Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Rona Yaeger,Jared Weiss,Meredith Pelster,Alexander I. Spira,Minal Barve,Sai‐Hong Ignatius Ou,Ticiana Leal,Tanios Bekaii‐Saab,Cloud P. Paweletz,Grace A Heavey,James G. Christensen,Karen Velastegui,Thian Kheoh,Hirak Der-Torossian,Samuel J. Klempner

The New England Journal of Medicine（2023）

引用 49|浏览0

暂无评分

摘要

Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a KRAS G12C inhibitor with an epidermal growth factor receptor antibody could be an effective clinical strategy.

查看译文

关键词

colorectal cancer,cetuximab,adagrasib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要